Aflac (AFL) Set to Post Earnings on Wednesday

Aflac (NYSE:AFL) is projected to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Aflac to post earnings of $1.80 per share and revenue of $4.12 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Aflac (NYSE:AFL) last announced its earnings results on Thursday, August 6th. The financial services provider reported $1.75 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.01). The business had revenue of $4.22 billion for the quarter, compared to the consensus estimate of $4.11 billion. During the same period in the previous year, the company posted $1.78 earnings per share. The company’s revenue was down 1.0% on a year-over-year basis. On average, analysts expect Aflac to post $7.04 EPS for the current fiscal year and $7.70 EPS for the next fiscal year.

Aflac Trading Up 1.0%

Shares of AFL stock opened at $122.16 on Wednesday. Aflac has a 1 year low of $105.43 and a 1 year high of $130.22. The firm’s 50 day moving average is $116.40 and its 200-day moving average is $115.61.

Aflac Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Wednesday, August 19th were issued a $0.61 dividend. The ex-dividend date of this dividend was Wednesday, August 19th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 2.0%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Mizuho dropped their price objective on shares of Aflac from $116.00 to $107.00 and set an “underperform” rating for the company in a research report on Wednesday, October 7th. TD Cowen reaffirmed a “hold” rating and set a $110.00 price objective (up from $101.00) on shares of Aflac in a report on Wednesday, July 22nd. UBS Group reiterated a “neutral” rating and issued a $125.00 price objective (up from $124.00) on shares of Aflac in a research report on Tuesday, October 6th. Wells Fargo & Company lowered their target price on Aflac from $122.00 to $116.00 and set an “equal weight” rating for the company in a research note on Monday, October 12th. Finally, Raymond James Financial boosted their target price on Aflac from $119.00 to $123.00 in a research report on Wednesday, August 26th. Four investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $117.20.

Insider Transactions at Aflac

In other news, major shareholder Post Holdings Co. Ltd. Japan sold 113,611 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $118.53, for a total value of $13,466,311.83. Following the transaction, the insider owned 50,134,329 shares of the company’s stock, valued at approximately $5,942,422,016.37. This trade represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 713,662 shares of company stock worth $83,323,978. Corporate insiders own 0.80% of the company’s stock.

About Aflac

Aflac Incorporated (NYSE:AFL) is an insurance company specializing in supplemental health and life insurance. Through its policies, the company helps individuals and families manage expenses that may not be fully covered by major medical insurance, including deductibles, copayments and other out-of-pocket costs.

Aflac offers products such as accident, cancer, critical illness, hospital indemnity, dental and vision, disability, life and long-term care insurance. Many of its supplemental policies provide cash benefits directly to policyholders, who can generally use the funds according to their individual needs.